Last $25.68 USD
Change Today +0.03 / 0.12%
Volume 59.9K
TKPYY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutic-sp adr (TKPYY) Snapshot

Open
$25.68
Previous Close
$25.65
Day High
$25.68
Day Low
$25.57
52 Week High
02/24/15 - $25.88
52 Week Low
12/16/14 - $20.36
Market Cap
40.6B
Average Volume 10 Days
24.1K
EPS TTM
--
Shares Outstanding
1.6B
EX-Date
09/25/14
P/E TM
--
Dividend
$0.76
Dividend Yield
3.20%
Current Stock Chart for TAKEDA PHARMACEUTIC-SP ADR (TKPYY)

Related News

No related news articles were found.

takeda pharmaceutic-sp adr (TKPYY) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutic-sp adr (TKPYY) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥216.0M
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: ¥387.0M
Managing Director of Special Missions and Dir...
Total Annual Compensation: ¥93.0M
Chief Medical & Scientific Officer and Direct...
Total Annual Compensation: ¥332.0M
Compensation as of Fiscal Year 2014.

takeda pharmaceutic-sp adr (TKPYY) Key Developments

Takeda Pharmaceutical Company Limited Announces New Office in Biopolis, Singapore

Takeda Pharmaceutical Company Limited announced the inauguration of its new office in Biopolis, Singapore. The expanded space will host Takeda functions- its Emerging Markets Business Unit headquarters, Takeda Development Center Asia and Vaccine Business Unit. Consolidating and streamlining Singapore operations into a centralized office will enhance efficiencies and enable Takeda to better understand and meet the needs of patients and customers in Asia. The new office will house the Takeda Emerging Markets Business Unit, including Asia-Pacific, as well as the Takeda Vaccine Business Unit and the regional Research and Development Center.

Queen Mary University of London and Takeda Pharmaceutical Company Limited Collaborate to Develop New Therapies in Gastroenterology

Queen Mary University of London and Takeda Pharmaceutical Company Limited have announced a research collaboration to develop new therapies in gastroenterology. QMUL's Neurogastroenterology Group aims to understand the neuromuscular control of GI function, with an emphasis on brain-gut interactions and GI motility. The focus of the research alliance will be GI sensory and motor mechanisms underlying functional bowel disorders and GI motility disorders. Takeda's GI Drug Discovery Unit will work closely with experts from the School of Medicine and Dentistry's Neurogastroenterology and Immunology groups on several areas of research, including identifying novel therapeutic targets and researching the effect of compounds with novel mechanisms of action in established QMUL translational assays. QMUL researchers Professors Gareth Sanger and Ashley Blackshaw, Dr. David Bulmer and Dr. Andrew Stagg will collaborate in this three-year research programme.

Takeda Pharmaceutical Company Limited Starts Construction of Shin-Tokyo Takeda Building

Takeda Pharmaceutical Real Estate Co Ltd. and Takeda Pharmaceutical Company Limited have started the construction of its Shin-Tokyo Takeda building. The new building will stand 24 stories above ground (approximately 123 meters) and have four underground floors. It is scheduled to be completed in 2017, after which Takeda will establish it as the company's new Tokyo head office in place of the current head office location at Nihonbashi 2-chome in Chuo-ku. The ground floor and second floor will be open for public use as a communal space, and tenants (shops) will be solicited for the B1 floor. The new building is to be constructed as a high-grade structure equipped with both a base isolation system and the latest BCP (business continuity planning) preparedness. Meanwhile, the plaza will have an open space designed for community utilization as an evacuation area in the event of a disaster.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPYY:US $25.68 USD +0.03

TKPYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.37 USD 0.00
Actavis plc $291.36 USD 0.00
Baxter International Inc $69.15 USD 0.00
Becton Dickinson and Co $146.72 USD -1.82
Eli Lilly & Co $70.17 USD +0.14
View Industry Companies
 

Industry Analysis

TKPYY

Industry Average

Valuation TKPYY Industry Range
Price/Earnings 64.1x
Price/Sales 2.8x
Price/Book 1.9x
Price/Cash Flow 14.0x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTIC-SP ADR, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.